Lupin launches Fluoxetine Tablets USP
22nd Aug 2019

Lupin has launched Fluoxetine Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic equivalent of Eli Lilly and Company’s Prozac Tablets, 10 mg and 20 mg. It is indicated in the treatment of major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Bulimia Nervosa and Panic Disorder. Fluoxetine Tablets USP, 10 mg and 20 mg (RLD: Prozac) had an annual sales of approximately USD 53 million in theUS (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.